bioSeedin Online Roadshow

6 biotech and pharma companies from 5 countries including United States, United Kingdom, France, Sweden and South Korea, are gathering in bioSeedin online roadshow to present their pipelines on nano-particle technology, drug delivery platform, CAR-T and etc., covering therapeutic areas such as oncology, CNS, metabolic diseases.



Don’t miss out this great opportunity to develop long-term relationships with worldwide biopharma companies! Register as our audience for FREE at  



Roadshow info:


  • Date: 26thOctober at 9:00 AM EST/ 3:00 PM CET/ 9:00 PM BJT
  • Duration: 2 hours
  • Each section 15 mins + 3 mins Q&A



Presentation order:

EST Time


9:00- 9:05 AM

Roadshow introduction, Judges introduction

9:05- 9:25

SN BioScience (South Korea)

9:25- 9:45

S. M. Discovery Group (UK)

9:45- 10:05

Leucid Bio (UK)

10:05- 10:25

Double Bound Pharmaceutical (SE, EU)

10:25- 10:45

Adocia (FR, EU)

10:45- 11:05

Luminary Therapeutics (MN, US)


Roadshow introduction, Judges introduction


  • bioSeedin Introduction
  • Judges introduction; judges’ info



SN BioScience (South Korea)



SN BioScience is a clinical-stage nano-medicine research and development company based in Seoul. It is best known for “SNB-101,” drug candidate for treating pancreatic cancer, and “double core-shell micelle” technology, which enables producing stable nano-sized micelle for poorly soluble drugs, according to the company.


SN BioScience is actively developing SNB-101(SN-38 lyophilized IV formulation) with proprietary polymeric nano-particle technology. SNB-101 is the first nano-DDS formulation with active metabolite of Irinotecan, SN-38 , and it has shown very promising phase 1 results in terms of efficacy (solid cancer including small cell lung cancer) and safety (no DLT diarrhea) as well as pre-clinical efficacy in gastric, colorectal, pancreatic, and lung cancer models.


Tag: double core-shell micelle technology; nano-particle technology; small cell lung cancer

Phase 2 ready asset- SN-38 is delivered by double core-shell micelle technology for solid cancer



  1. M. Discovery Group (SMDG) (UK)
  2. M. Discovery Group (SMDG) is a pre-clinical stage biotechnology company that has developed innovative patent-protected, proprietary therapeutic platforms NanoLigand Carriers TM (NLC), NanoLigand Blocks (TM) (NLB) for non-viral, targeted and receptor-mediated delivery of therapies and gene therapy. 

The library of novel Peptide Conjugate Nanosystems (TM)(PCN) is based on "safe-by-design" and "simple-by-design" concepts that actively generate new conjugated modalities and is also capable of delivering therapeutic molecules to the target cells and exert pharmacological activity. The major highlight of these patented therapeutic platforms is the ability to cross biological barriers, particularly the Blood-Brain Barrier (BBB) and deliver therapeutic molecules to cells in the brain parenchyma. This makes the SMDG’s capability unique and differentiated from other companies in Europe, USA and globally that are limited by their delivery capabilities. 


SMDG is now utilizing its novel and innovative platforms in combination with nucleic acid design and has generated therapeutic modalities for central nervous system (CNS) diseases and other indications. SMDG has a growing pipeline of modalities as well as an expanding IP portfolio. 


Tag: NanoLigand delivery platform; CNS; Blood-Brain Barrier

NanoLigand Carriers and NanoLigand Blocks for non-viral, targeted, and receptor-mediated delivery of therapies and gene therapy. 



Leucid Bio (UK)



Leucid Bio is a Clinical-stage biotech company using its lateral CAR platforms to develop more controlled, safer, and longer-lasting CAR T therapies for a broad range of cancers, to improve treatment outcomes and save lives. Leucid’s next generation CAR T company developing differentiated lateral CARs that achieve enhanced tumour targeting and selectivity, provide better durability and functional persistence, deliver a step change in therapeutic approach, safety, and efficacy, addressing issues that have arisen with competitor programs, approach obviates the need for complex gene editing approaches being adopted by competitors.

Tag: longer-lasting CAR T therapies; Oncology; Autologous; Allogenic

Using its proprietary Lateral CAR platform, Leucid Bio has developed a pipeline of assets for the treatment of solid tumors and hematological malignancies.



Double Bond Pharmaceutical (DBP) (Sweden)

Double Bond Pharmaceutical is a fast-growing pharmaceutical company that develops and commercializes innovative first-in-class approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders. The aim of the company is to design better medicinal products for patients suffering from diseases such as cancer, inflammation, asthma, or diabetes since the primary end-point is the well-being of the patient.



Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. To this end, Double Bond Pharmaceutical’s scientific team has been working hard to overcome the drawbacks of widely available treatment options that have already proven their effectiveness. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy. Our vision is that medicines work best when they are delivered to the right place at the right time.



Tag: first-in-class; Launch CIS market; Glioblastoma

Phase 1 ready, First-in-class new formulations, target application asset for Glioblastoma.



Adocia (FR)



Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.


Adocia currently has four assets in the clinic (Phase 1 to 3) and 3 in preclinical development. Adocia has established a strong partnership with Chinese insulin leader Tonghua Dongbao, to which two assets have been licensed out for Asia and Middle-East territories. An exclusivity agreement has recently been signed with Sanofi regarding M1Pram, a potential first-in-class treatment to address diabetes and obesity.


Adocia is listed on the regulated market of Euronext Paris and holds more than 25 patent families.


Tag: oral peptide delivery technology; long-acting drug delivery platform; Clinical asset

Oral peptide delivery asset first-in-class treatment to address diabetes and obesity.



Luminary Therapeutics (MN, US)



Luminary is a clinical-stage CAR-T therapy company with a novel allogeneic manufacturing platform where our CAR and or TCR development utilizes gamma delta cells. What makes our allogeneic therapeutics unique is that our final drug product includes the combinatory power of both the Vẟ1 and Vẟ2 gamma delta cells, giving our therapies the power of both innate and adaptive cancer clearing power. We have multiple solid tumor targets under development with a proprietary signaling method to ensure T-cell persistence. Additionally, our Ligand BAFF CAR for hematologic cancers is designed with 3 antigen receptors specifically designed to overcome antigen escape.



Tag: clinical-stage; allogeneic CAR-T; TCR

A clinical-stage allogeneic CAR-T therapy by using gamma delta cells for oncology



    San Jose
    Stay Connected and Get Updates
    Subscribe newsletter